Phase 4 N=299 Study of Triamcinolone Acetonide on the Growth Velocity of Children, Ages 3 to 9, With Perennial Allergic Rhinitis (PAR)
Rhinitis, Allergic, Perennial
Primary: Growth Velocity — 6.09; 5.65 cm/year — p=0.0096
Clinical Trial Search
Completed trials with posted results — search by concept, filter by the parameters that matter at the bedside.
Phase 4 N=15 Long-Term One Year Use of Alefacept (Amevive®) in Moderate to Severe Chronic Plaque Type Psoriasis
Psoriasis
Primary: Efficacy — 1 #Participants
Phase 4 N=15 Comparing Effects of Two Fixed Combinations Ophthalmic Solutions on Ocular Blood Flow
Glaucoma
Primary: Retrobulbar Blood Flow (Peak Systolic Velocity) as Measured by Color Doppler Imaging in the Nasal Short Posterior Ciliary Artery — 8.61; 8.02 Centimeters per second (cm/s)
Phase 4 N=34 Trial to Study the Effect of Dose of Herpes Simplex Virus-2 (HSV-2) Suppressive Therapy on HSV and HIV
Genital Herpes · HIV Infection
Primary: The Quantity of HIV-1 RNA in Plasma While on 400 mg Twice Daily of Acyclovir Versus 1000 mg Twice Daily of Valacyclovir. — 4.08; 3.68 log10 copies/mL — p=<0.001
Phase 4 N=125 Low and High Dose Zonisamide in Children as Monotherapy
Epilepsy
Primary: Percentage of Participants Who Were Assessed As Seizure Free — 63.1; 57.6 percentage of participants
Phase 4 N=752 Efficacy and Safety of Acetaminophen, Aspirin and Caffeine With Sumatriptan in the Acute Treatment of Migraine
Pain, Migraine
Primary: Percent of Subjects Who Are Pain Free at 2 Hours. — 34.7; 44.9; 26.4 Percent of participants
Phase 4 N=255 Multicenter Uveitis Steroid Treatment (MUST) Trial
Uveitis
Primary: Change in Best-corrected Visual Acuity (Change in the Numbers of Letters Read From a Standard ETDRS Eye Chart) From Baseline to 24 Months in Eyes With Uveitis — 6.0; 3.2…
Phase 4 N=38 Study of Add-on Ambrisentan Therapy to Background Phosphodiesterase Type-5 Inhibitor (PDE5i) Therapy in Pulmonary Arterial Hypertension (ATHENA-1)
Pulmonary Arterial Hypertension
Primary: Change From Baseline in Pulmonary Vascular Resistance (PVR), Last Observation Carried Forward (LOCF) — 761.2; 731.6; 758.0; 703.6 dynes sec/cm^5
Phase 4 N=199 The Clinical Response of Choline Acetyltransferase and Apolipoprotein Epsilon Gene Polymorphisms to Donepezil in Alzheimer's Disease
Alzheimer's Disease
Primary: CERAD-K (the Korean Version of the Consortium to Establish a Registry for Alzheimer's Disease) — 8.28; 7.31; 17.86; 10.62 Units on Scale
Phase 4 N=286 A Study Comparing Aczone® Plus Differin® Versus Duac® Plus Differin® in Patients With Severe Facial Acne
Acne Vulgaris
Primary: Percentage of Participants With at Least a One Point Decrease in the Global Acne Assessment Score (GAAS) at Week 12 — 69.7; 81.4 Percentage of participants
Phase 4 N=87 Symptomatic Relief of Acute Dyspeptic Pain in Emergency Department With Pantoprazole
Dyspepsia · Emergency · Pain
Primary: Pain Scores on the 100-millimeter Visual Analog Scale (VAS) at 1 Hour After Treatment — 17; 19 millimeter — p=0.6
Phase 4 N=66 Compare the Effect on Cognitive Functioning of Two Formulations of Seroquel, Seroquel XR and IR in Patients With Stable Schizophrenia
Schizophrenia
Primary: Mean for Attentional Standardised Composite Score Based on Performance Scores From the CogState Test Battery Domains Detection (Speed of Processing)and Identification…
Phase 4 N=200 Comparative Study of Zonisamide and Carbamazepine as an Initial Monotherapy: Efficacy and Safety Evaluation
Epilepsy
Primary: The Percentage of Participants With Seizure Free Rate — 73.7; 83.1 percentage of participants
Phase 4 N=13 Assessment of Alcon's Ocular Image Quantification System
Allergic Conjunctivitis
Primary: Change From Baseline in Patient-Assessed Ocular Itching, Environmental Exposure Chamber (EEC), at 3 Hours — -1.63; -1.11 Units on a scale
Phase 4 N=83 Prineo (Dermabond Protape) Versus Sutures for Full-thickness Surgical Incisions
Surgical Incisions
Primary: Continuous Apposition of the Skin Edges Without Wound Dehiscence or Re-closure as Measured by the Upper Limit of 95% Confidence Interval in Proportion of Successes for…